What is ORIAHNN used for?

ORIAHNN is used to manage heavy menstrual bleeding caused by uterine fibroids in women who have not gone through menopause.

Can ORIAHNN cause bone loss?

Yes, ORIAHNN may cause a decrease in bone mineral density, and this loss might not be fully reversible after you stop the medicine.

How long can I safely take ORIAHNN?

Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss.

What should I do if I miss a dose of ORIAHNN?

Take the missed dose within 4 hours of the scheduled time; if it has been longer than 4 hours, skip the dose and take the next one at the usual time.

Does ORIAHNN increase the risk of blood clots?

Yes, the hormone components in ORIAHNN can increase the risk of blood clots, stroke, and heart attack.

Can I take ORIAHNN if I am pregnant?

No, ORIAHNN is not for use during pregnancy and should be stopped immediately if pregnancy is confirmed.

Will ORIAHNN affect my hair?

Some users may experience hair loss or thinning, which might not completely go away after stopping the drug.

Should I avoid grapefruit juice with ORIAHNN?

Yes, you should avoid grapefruit juice while taking this medication.

elagolix | CAS 834153-87-6 | HEAUOKZIVMZVQL

Loading compound...

GnRH receptor antagonist and hormone combination therapy

ORIAHNN is a combination medication containing elagolix, estradiol, and norethinadrone acetate. It is used to manage heavy menstrual bleeding caused by uterine fibroids (leiomyomas) in women who have not yet reached menopause. Because the medication can lead to bone density loss, it is generally recommended for use for no more than 24 months.

How it worksORIAHNN works by blocking a hormone called GnRH. This lowers the levels of other hormones that cause heavy bleeding, while the included estrogen and progestin help manage side effects like bone loss.

Brand names:Oriahnn

Used for

Heavy menstrual bleeding associated with uterine fibroids (leiomyomas) in premenopausal women

Conditions

Uterine leiomyomas (fibroids)

Class

GnRH antagonistHormone therapyGnRH receptor antagonist and hormone combination therapyReproductive systemSkeletal system

How to take

FormsCapsules

RoutesOral

Take one morning capsule (containing elaogolix, estradiol, and norethinadrone acetate) and one evening capsule (containing only elaogolix) every day at approximately the same time.

You can take these capsules with or without food. If you miss a dose, take it within 4 hours; otherwise, skip it and take the next dose at your regular time.

Missed dose: If you miss a dose, take it within 4 hours. If more than 4 hours have passed, skip it and take your next dose at the regular time.

Key warnings

ORIAHNN increases the risk of serious blood clots, stroke, and heart attack. This risk is higher for women over 35 who smoke or have uncontrolled high blood pressure.

·ORIAHNN increases the risk of serious blood clots, stroke, and heart attack. This risk is higher for women over 35 who smoke or have uncontrolled high blood pressure.
·Risk of serious blood clots or vascular events.
·Potential for bone density loss that may not be reversible.
·Risk of mood changes, including depression or suicidal thoughts.
·Risk of liver injury.
·Risk of allergic reactions to FD&C Yellow No. 5.
·May make it harder to tell if you are pregnant due to changes in bleeding.

Do not use if

·Current or history of blood clots (thromboembolic disorders).
·Known osteoporosis.
·Current or history of breast cancer or other hormone-sensitive cancers.
·Known liver disease or impairment.
·Undiagnosed abnormal uterine bleeding.
·Pregnancy.
·Known allergy to any ingredients in ORIAHNN.
·Use of OAATP1B1 inhibitors.

Side effects

Common

Hot flashesHeadacheFatigueChanges in menstrual bleeding patterns

Serious

·Blood clots (thrombosis), stroke, or heart attack
·Loss of bone density (bone loss)
·Changes in mood or suicidal thoughts
·Liver problems
·High blood pressure
·Hair loss (alopecia)
·Vision changes

Seek help if

·Sudden vision changes
·Signs of liver injury (like jaundice)
·New or worsening depression or anxiety
·Signs of a blood clot (like leg swelling or chest pain)
·Severe headache or high blood pressure

Interactions

·Strong CYP3A inducers (like certain medications) may make ORIAHNN less effective.
·Strong CYP3A inhibitors may increase the levels of ORIAHNN in your body, raising the risk of side effects.
·OAATP1B1 inhibitors are contraindicated because they can significantly increase elaogolix levels.
·Certain drugs like digoxin, midaolam, rosuvastatin, and omeprazole may have their levels changed when taken with ORIAHNN.
·Avoid grapefruit juice while taking this medication.

FoodHigh-fat meals may decrease the absorption of the components in ORIAHNN.

Special populations

PregnancyORIAHNN should not be used during pregnancy as it may increase the risk of early pregnancy loss. If you become pregnant while taking this medication, stop taking it immediately.

PediatricThe safety and effectiveness of ORIAHNN in children have not been established.

Talk to your doctor

Monitor

·Bone mineral density (BMD)
·Blood pressure
·Liver function (transaminase levels)
·Signs of blood clots
·Mood changes
·Vision changes

Questions to ask

·What is my risk for bone loss while taking ORIAHNN?
·How will this medication affect my blood pressure?
·Should I take calcium or vitamin D supplements with this?
·Can I continue taking my current medications with ORIAHNN?

Pharmacokinetics

Protein bindingElaogolix is 80% bound to human plasma proteins; Estradiol is 98%; Norethinadrone is 97%.

MetabolismElaogolix is primarily metabolized by CYP3A, with minor pathways including CYP2D6 and CYP2C8.

Practical

OverdoseAn overdose of this hormone combination may cause nausea, vomiting, breast tenderness, stomach pain, sleepiness, and fatigue. Seek medical help if an overdose is suspected.

DisposalDispose of unused medication via a take-back option if available, or follow FDA instructions for household trash disposal. Do not flush down the toilet.

Ingredients

Allergens

lactosecorngelatinFD&C Yellow #5 (tartrazine)

Inactive

anhydrous sodium carbonatepolyethylene glycol 3350crosspovidonecolloidal silicon dioxidemagnesium stearatepolyvinyl alcoholtitanium dioxidepolyethylene glycoltalcpurified waterlactose monohydratestarch (corn)copovidonehypromellosetriacetingelatin capsule shellFD&C Red #40FD&C Yellow #5FD&C Yellow #6FD&C Blue #2FDA/E172 yellow iron oxideshellacdehydrated alcoholisopropyi alcoholbutyl alcoholpropylene glycolstrong ammonia solutionblack iron oxidepotassium hydroxide

Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.